VisEn Medical Names John Kleijne as Vice President Commercialization and Partnerships, Europe
VisEn Medical Names John Kleijne as Vice President Commercialization and Partnerships, Europe
Appointment Enhances VisEn's Expansion and Leadership in Fluorescence Molecular Imaging Worldwide
Ze-gen, Inc. Secures $4.5 Million in Series A Funding from Flagship Ventures and VantagePoint Venture Partners
Ze-gen, Inc. Secures $4.5 Million in Series A Funding from Flagship Ventures and VantagePoint Venture Partners
Adds Seasoned CleanTech Investors to Board of Directors
Mascoma Corporation Appoints T. Jack Huggins to Board of Directors
Mascoma Corporation Appoints T. Jack Huggins to Board of Directors
Brings Expertise in Ethanol, Agribusiness, Agronomy, and Conservation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mascoma Corporation, a leader in low-carbon cellulosic biomass-to-ethanol production through advanced biotechnology, today announced that T. Jack Huggins has joined the company’s Board of Directors.
Granholm Says New Ethanol Plant to Put Michigan First in Race to Turn "Wood to Wheels"
Granholm Says New Ethanol Plant to Put Michigan First in Race to Turn "Wood to Wheels"
Mascoma to invest here, partner with MSU, Michigan Tech
Ze-gen, Inc. Hosts Ribbon Cutting at Demonstration Facility in New Bedford
Ze-gen, Inc. Hosts Ribbon Cutting at Demonstration Facility in New Bedford
Facility will pilot company’s innovative waste gasification and renewable energy generation technology
.jpg){kind=small}
Robert Walsh Appointed President of LS9, Inc., the Renewable Petroleum Company™
Robert Walsh Appointed President of LS9, Inc., the Renewable Petroleum Company™
Oil industry veteran to direct commercial development of DesignerBiofuels™ Products
SAN CARLOS, CA – July 30, 2007 – LS9, Inc., the Renewable Petroleum Company™, has named Robert Walsh its new President, effective immediately. Walsh will lead the rapid commercialization of LS9 DesignerBiofuels™ products, including a pilot facility leading to commercial production.
LS9 Wins Presidential Green Chemistry Challenge Award
LS9 Wins Presidential Green Chemistry Challenge Award
Renewable Petroleum™ technology efficiently converts renewable raw materials into low-carbon fuels and chemicals
SOUTH SAN FRANCISCO, CA -- June 21, 2010 -- LS9, Inc., the Renewable Petroleum Company™, today announced that it has won the U.S. Environmental Protection Agency’s (EPA) highest environmental honor for its revolutionary Renewable Petroleum™ technology that converts sustainable, plant-based materials into low-carbon fuels and chemicals.
Fontinalis Partners Announces Investment in Everyday Solutions the Leading Provider of GPS-Driven School Transportation Information Management Systems
Fontinalis Partners Announces Investment in Everyday Solutions the Leading Provider of GPS-Driven School Transportation Information Management Systems
Acton, MA / Detroit, MI USA, Jun. 18, 2010 — Fontinalis Partners, LLC, a Michigan-based strategic investment firm, today announced that it has invested in Everyday Solutions, Inc., the leading provider of GPS-driven school transportation information management systems. Existing investors Ascent Venture Partners and Flagship Ventures also participated. The financial terms of the transaction were not disclosed.
LS9, Creator of Synthetic Microbes to Make Biofuel, Edges Toward Moment of Truth
LS9, Creator of Synthetic Microbes to Make Biofuel, Edges Toward Moment of Truth
Every hot startup has to put up or shut up at some point. This is when it’s time to stop talking about the gee-whiz founding idea and scientific progress. It’s the point when a company needs to prove it can operate a disciplined, sustainable business. The moment is fast approaching for LS9.
Ensemble Discovery and Roche Initiate Research Collaboration to Apply New Diagnostic Technology to Optimize Cancer Therapy
Ensemble Discovery and Roche Initiate Research Collaboration to Apply New Diagnostic Technology to Optimize Cancer Therapy
Collaboration will enable analysis of critical drug target family in patient cancer biopsies and selection of appropriate therapy